EDITEditas Medicine, Inc.
$2.39-33% 1Y
$2.39
$1.6652 weeks$3.74
Is the price fair?
What EDIT's price assumes
Editas Medicine, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 8.22× revenue.
8.22
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 3.67
Price / book · as of 2026-Q2
- EV / sales
- 4.91
EV / sales
Details›
- Price / bookas of 2026-Q2
- 3.67
- EV / EBIToperating margin −161%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 4.91
- Market capitalisation153.6 million shares, counted Jul 31, 2026
- $367M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.